The Diane Barton Database

The Clearity Foundation has provided its molecular profiling service for over three years and has profiled the tumors of nearly 200 women. The foundation captures this information in The Diane Barton Database, named in memory of Dr. Diane Barton, who died of ovarian cancer in 2005. Her brother, David Barton, with support from his trainers, employees and clientele at DavidBartonGym, has provided funding to The Clearity Foundation to honor her legacy as “a healer, an educator and a world class physician”, as she was described by those who worked with her. Dr. Barton worked tirelessly to promote ovarian cancer awareness and continues to this day through The Diane Barton Database in her memory.

The Diane Barton Database has captured the results from tests that measure the expression of tumor biomarkers in women with ovarian cancer. Each woman is tracked over time and their treatment outcomes are recorded in the database although each person’s confidential information is protected. With this database, Clearity and physicians are correlating tumor profiles with outcomes and identifying tumors that have similar profiles. The hope is that these data will provide additional evidence for the treatment paradigm for ovarian cancer on an individual basis.

Molecular profiling utilizes a combination of technologies such as immunohistochemistry, fluorescence in situ hybridization (FISH), mutational analysis and microarrays all run by CLIA-certified labs. These assays measure the level and state of specific proteins, RNA and DNA in the tumor to identify which pathways are important for its growth and survival. By identifying the alterations in each tumor’s information pathways, molecular profiling can individualize a patient’s treatment by matching the tumor with one or more drugs that target those pathways. These drugs are expected to be the most effective for that individual. In addition, a profiling test panel includes molecular markers that indicate whether a patient’s tumor is likely to be resistant to certain chemotherapy agents. By screening for chemo-resistance, it’s possible to prioritize treatments that have a better chance to attack the tumor.

H Score= intensity x % positive cells. The box plot shows the range of expression levels for each marker in the ovarian cancer database. Boxes = second and third quartiles. Line = median. Whiskers = highest and lowest values. Red box = individual patient data.

Diane Barton was born in 1959 in Queens, New York, graduated from Cornell University in 1980 and Temple Medical School in 1984. She was board certified in Internal and Geriatric Medicine and was a fellow of the American College of Physicians and a leader in the American Medical Women’s Association. Diane rose to the rank of Associate Professor of Medicine at Robert Wood Johnson Medical School, Camden Campus and was recognized countless times as a “Top Doc” in peer surveys and by South Jersey, New Jersey and Philadelphia magazines. She was also chosen as a Top Doc for women in 2000 and as one of the Top Docs in the US in 1999 and 2002. In 1999, Diane was diagnosed with ovarian cancer and in 2004, established a complementary medicine program at Cooper Hospital that was renamed The Diane Barton Complementary Medicine program after her death in 2005.

The Diane Barton Database is powered by

With locations in New York, Chicago, Miami and Seattle, DavidBartonGym features state-of-the-art equipment and an expertly trained staff, hand-picked by owner David Barton, in order to make members "LookBetterNaked.” www.davidbartongym.com